ArticleMolecular neurobiology2025
AMPK Activation by ENERGI Ameliorates Behavioral and Synaptic Deficits in a Mouse Model of Autism.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Equol as a Multitarget Agent Against Neurodegeneration: Mechanistic Insights into Its Molecular Modulation.Neuromolecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Autism spectrum disorder (ASD), a neurodevelopmental disorder, is characterized by synaptic dysregulation as its underlying pathophysiological mechanism. AMP-activated protein kinase (AMPK), an intracellular energy sensor, plays a pivotal role in regulating synaptic integrity and function. Current treatments for ASD exhibit limited benefits in alleviating the core symptoms of ASD. Consequently, we investigated the therapeutic potential of ENERGI, a novel AMPK-activating compound, in a valproate (VPA)-induced mouse model of ASD. ENERGI was administered via drinking water to VPA-induced ASD offspring. After 7 days of treatment, ENERGI gradually alleviated social defects, repetitive behaviors, and emotional comorbidities in VPA-induced ASD offspring. At the synaptic level, ENERGI treatment restored aberrant plasticity, spine structure, and dendritic arborization in the hippocampus of VPA-induced ASD offspring. Notably, the curative effects of ENERGI in VPA-induced ASD offspring were equivalent to those of D-cycloserine (DCS), a known therapeutic candidate for ASD. Moreover, ENERGI demonstrated superior efficacy in restoring spine abnormalities than DCS. Mechanistically, 7-day ENERGI treatment reversed the reduction in AMPK phosphorylation, and normalized the elevated PSD95 and synaptic GluA2 levels in VPA-induced ASD offspring, whereas DCS treatment only rescued the synaptic GluA2 levels. Overall, these findings suggest that AMPK activation by ENERGI effectively reverses behavioral and synaptic deficits in a preclinical ASD model, supporting AMPK as a promising target for developing novel ASD therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.